Search research articles
Contact Us
Filters
Showing results (51-60 of 72) with videos related to
Page
of 8
Sort By:
European Urology
|
June 20, 2016
Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
J Connor Wells, Igor Stukalin, Craig Norton, et al.
Frontiers in Oncology
|
December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database
Gabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
European Urology Oncology
|
August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers
Nieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.
Lancet (London, England)
|
July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
Christopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
The Prostate
|
November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer
Christopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
Cancer
|
August 7, 2020
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer
Tian Zhang, Michael R Harrison, Peter H O'Donnell, et al.
European Urology
|
April 7, 2026
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial
Minas P Economides, Peter H O'Donnell, Ajjai S Alva, et al.
JCO Precision Oncology
|
November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate Cancer
Fadi Taza, Albert E Holler, Wei Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 24, 2024
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Charles B Nguyen, Melissa A Reimers, Chamila Perera, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 72) with videos related to
Sort By:
Page
of 8
European Urology
|
June 20, 2016
Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
J Connor Wells, Igor Stukalin, Craig Norton, et al.
Frontiers in Oncology
|
December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database
Gabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
European Urology Oncology
|
August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers
Nieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.
Lancet (London, England)
|
July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
Christopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
The Prostate
|
November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer
Christopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
Cancer
|
August 7, 2020
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer
Tian Zhang, Michael R Harrison, Peter H O'Donnell, et al.
European Urology
|
April 7, 2026
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial
Minas P Economides, Peter H O'Donnell, Ajjai S Alva, et al.
JCO Precision Oncology
|
November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate Cancer
Fadi Taza, Albert E Holler, Wei Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 24, 2024
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Charles B Nguyen, Melissa A Reimers, Chamila Perera, et al.
Page
of 8